Litcius/Paper detail

Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China

Zonglin Dai, Irene Ol Wong, Chan Xie, Wenxiong Xu, Yu Xiang, Liang Peng, Eric H. Y. Lau

2021Clinical Microbiology and Infection16 citationsDOIOpen Access PDF

Topics & Concepts

EntecavirMedicinePegylated interferonCost effectivenessHBeAgHBsAgCost-effectiveness analysisInternal medicineHepatitis B virusChronic hepatitisImmunologyVirusLamivudineRisk analysis (engineering)RibavirinHepatitis B Virus StudiesHepatitis C virus researchHIV/AIDS drug development and treatment
Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China | Litcius